Latest news

AbbVie bets $1.2B on psychedelic breakthrough for depression

AbbVie bets $1.2B on psychedelic breakthrough for depression

Joachim Eeckhout
LB Pharma targets IPO lifeline to fund schizophrenia drug trial

LB Pharma targets IPO lifeline to fund schizophrenia drug trial

Joachim Eeckhout
Daily Snap - 22. August 2025

Daily Snap - 22. August 2025

Joachim Eeckhout
Gilead bets big on in vivo cell therapy with $350M Interius buy

Gilead bets big on in vivo cell therapy with $350M Interius buy

Eduardo Longoria
FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

Eduardo Longoria
Daily Snap - 21. August 2025

Daily Snap - 21. August 2025

Joachim Eeckhout
Celldex shares drop 18% after it follows Allakos’ footsteps in eosinophilic esophagitis

Celldex shares drop 18% after it follows Allakos’ footsteps in eosinophilic esophagitis

Eduardo Longoria
Jazz bets $42.5M on Saniona’s next-gen epilepsy drug to avoid Potiga’s pitfalls

Jazz bets $42.5M on Saniona’s next-gen epilepsy drug to avoid Potiga’s pitfalls

Eduardo Longoria
Daily Snap - 20. August 2025

Daily Snap - 20. August 2025

Joachim Eeckhout
Halda strikes $1B AI-powered deal with VantAI to fuel “hold-and-kill” cancer drugs

Halda strikes $1B AI-powered deal with VantAI to fuel “hold-and-kill” cancer drugs

Eduardo Longoria
Viking's stock tanks after obesity pill delivers weight loss with side effects

Viking's stock tanks after obesity pill delivers weight loss with side effects

Eduardo Longoria
Reunion’s psilocybin like drug shows promise for postpartum depression, moves to Phase 3

Reunion’s psilocybin like drug shows promise for postpartum depression, moves to Phase 3

Eduardo Longoria
FirstBack
12345678
Next Last